Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1961 2
1963 1
1964 3
1966 1
1967 1
1968 1
1969 1
1970 1
1971 1
1973 1
1974 1
1975 1
1976 2
1977 2
1978 2
1979 2
1981 3
1985 1
1986 3
1987 1
1988 2
1989 2
1991 7
1992 3
1993 11
1994 7
1995 12
1996 14
1997 13
1998 4
1999 9
2000 7
2001 13
2002 12
2003 6
2004 12
2005 12
2006 12
2007 16
2008 18
2009 21
2010 22
2011 30
2012 23
2013 20
2014 21
2015 26
2016 26
2017 28
2018 22
2019 20
2020 35
2021 37
2022 33
2023 29
2024 28
2025 25
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

612 results

Results by year

Filters applied: . Clear all
Page 1
Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial.
Hernández G, Ospina-Tascón GA, Damiani LP, Estenssoro E, Dubin A, Hurtado J, Friedman G, Castro R, Alegría L, Teboul JL, Cecconi M, Ferri G, Jibaja M, Pairumani R, Fernández P, Barahona D, Granda-Luna V, Cavalcanti AB, Bakker J; The ANDROMEDA SHOCK Investigators and the Latin America Intensive Care Network (LIVEN); Hernández G, Ospina-Tascón G, Petri Damiani L, Estenssoro E, Dubin A, Hurtado J, Friedman G, Castro R, Alegría L, Teboul JL, Cecconi M, Cecconi M, Ferri G, Jibaja M, Pairumani R, Fernández P, Barahona D, Cavalcanti AB, Bakker J, Hernández G, Alegría L, Ferri G, Rodriguez N, Holger P, Soto N, Pozo M, Bakker J, Cook D, Vincent JL, Rhodes A, Kavanagh BP, Dellinger P, Rietdijk W, Carpio D, Pavéz N, Henriquez E, Bravo S, Valenzuela ED, Vera M, Dreyse J, Oviedo V, Cid MA, Larroulet M, Petruska E, Sarabia C, Gallardo D, Sanchez JE, González H, Arancibia JM, Muñoz A, Ramirez G, Aravena F, Aquevedo A, Zambrano F, Bozinovic M, Valle F, Ramirez M, Rossel V, Muñoz P, Ceballos C, Esveile C, Carmona C, Candia E, Mendoza D, Sanchez A, Ponce D, Ponce D, Lastra J, Nahuelpán B, Fasce F, Luengo C, Medel N, Cortés C, Campassi L, Rubatto P, Horna N, Furche M, Pendino JC, Bettini L, Lovesio … See abstract for full author list ➔ Hernández G, et al. Among authors: espinosa e. JAMA. 2019 Feb 19;321(7):654-664. doi: 10.1001/jama.2019.0071. JAMA. 2019. PMID: 30772908 Free PMC article. Clinical Trial.
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
Piulats JM, Watkins C, Costa-García M, Del Carpio L, Piperno-Neumann S, Rutkowski P, Hassel JC, Espinosa E, de la Cruz-Merino L, Ochsenreither S, Shoushtari AN, Orloff M, Salama AKS, Goodall HM, Baurain JF, Nathan P. Piulats JM, et al. Among authors: espinosa e. Ann Oncol. 2024 Mar;35(3):317-326. doi: 10.1016/j.annonc.2023.11.013. Epub 2023 Dec 2. Ann Oncol. 2024. PMID: 38048850 Free article. Clinical Trial.
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Goodall HM, Ranade K, Holland C, Abdullah SE, Sacco JJ, Sato T. Carvajal RD, et al. Among authors: espinosa e. Nat Med. 2022 Nov;28(11):2364-2373. doi: 10.1038/s41591-022-02015-7. Epub 2022 Oct 13. Nat Med. 2022. PMID: 36229663 Free PMC article. Clinical Trial.
[Inflammatory myopathies].
Espinosa E. Espinosa E. Rev Neurol. 1996 Nov;24(135):1376-81. Rev Neurol. 1996. PMID: 8974740 Review. Spanish. No abstract available.
Special Issue "Lignocellulosic Biomass II".
Rodríguez A, Espinosa E, Martín C. Rodríguez A, et al. Among authors: espinosa e. Molecules. 2023 Aug 24;28(17):6230. doi: 10.3390/molecules28176230. Molecules. 2023. PMID: 37687061 Free PMC article.
Sequence of therapies for advanced BRAFV600E/K melanoma.
Gonzalez-Cao M, Rosell R, Martin Algarra S, Puertolas T, Espinosa E. Gonzalez-Cao M, et al. Among authors: espinosa e. Ann Transl Med. 2023 Mar 31;11(6):270. doi: 10.21037/atm-23-165. Epub 2023 Feb 14. Ann Transl Med. 2023. PMID: 37082692 Free PMC article. No abstract available.
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.
Sacco JJ, Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Holland C, Sato T. Sacco JJ, et al. Among authors: espinosa e. J Immunother Cancer. 2024 Jun 6;12(6):e009028. doi: 10.1136/jitc-2024-009028. J Immunother Cancer. 2024. PMID: 38844408 Free PMC article. Clinical Trial.
Special Issue "Lignocellulosic Biomass".
Rodríguez A, Espinosa E. Rodríguez A, et al. Among authors: espinosa e. Molecules. 2021 Mar 9;26(5):1483. doi: 10.3390/molecules26051483. Molecules. 2021. PMID: 33803258 Free PMC article.
612 results